{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T16:12:21Z","timestamp":1769184741215,"version":"3.49.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Heart Fail Rep"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s11897-019-0421-4","type":"journal-article","created":{"date-parts":[[2019,2,14]],"date-time":"2019-02-14T05:26:56Z","timestamp":1550122016000},"page":"32-37","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Vasodilator Therapies in the Treatment of Acute Heart Failure"],"prefix":"10.1007","volume":"16","author":[{"suffix":"Jr","given":"Daniel B.","family":"Holt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter S.","family":"Pang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,2,14]]},"reference":[{"issue":"12","key":"421_CR1","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.1161\/CIR.0000000000000558","volume":"137","author":"EJ Benjamin","year":"2018","unstructured":"Benjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang AR, Cheng S, et al. American Heart Association Council on epidemiology and prevention statistics committee and stroke statistics subcommittee. Heart disease and stroke statistics-2018 update: a report from the American Heart Association. Circulation. 2018;137(12):e67\u2013e492. \n                      https:\/\/doi.org\/10.1161\/CIR.0000000000000558\n                      \n                    .","journal-title":"Circulation"},{"issue":"3","key":"421_CR2","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1161\/HHF.0b013e318291329a","volume":"6","author":"PA Heidenreich","year":"2013","unstructured":"Heidenreich PA, Albert NM, Allen LA, American Heart Association Advocacy Coordinating Committee, Council on Arteriosclerosis, Thrombosis and Vascular Biology, Council on Cardiovascular Radiology and Intervention, et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail. 2013;6(3):606\u201319. \n                      https:\/\/doi.org\/10.1161\/HHF.0b013e318291329a\n                      \n                    .","journal-title":"Circ Heart Fail"},{"issue":"7","key":"421_CR3","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/j.amjcard.2007.11.061","volume":"101","author":"LR Loehr","year":"2008","unstructured":"Loehr LR, Rosamond WD, Chang PP, Folsom AR, Chambless LE. Heart failure incidence and survival (from the atherosclerosis risk in communities study). Am J Cardiol. 2008;101(7):1016\u201322. \n                      https:\/\/doi.org\/10.1016\/j.amjcard.2007.11.061\n                      \n                    .","journal-title":"Am J Cardiol"},{"issue":"3","key":"421_CR4","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.jchf.2014.01.006","volume":"2","author":"AB Storrow","year":"2014","unstructured":"Storrow AB, Jenkins CA, Self WH, Alexander PT, Barrett TW, Han JH, et al. The burden of acute heart failure on U.S. emergency departments. JACC Heart Fail. 2014;2(3):269\u201377. \n                      https:\/\/doi.org\/10.1016\/j.jchf.2014.01.006\n                      \n                    .","journal-title":"JACC Heart Fail"},{"issue":"2","key":"421_CR5","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.ahj.2013.05.014","volume":"166","author":"YW Wong","year":"2013","unstructured":"Wong YW, Fonarow GC, Mi X, Peacock WF IV, Mills RM, Curtis LH, et al. Early intravenous heart failure therapy and outcomes among older patients hospitalized for acute decompensated heart failure: findings from the acute decompensated heart failure registry emergency module (ADHERE-EM). Am Heart J. 2013;166(2):349\u201356. \n                      https:\/\/doi.org\/10.1016\/j.ahj.2013.05.014\n                      \n                    .","journal-title":"Am Heart J"},{"issue":"16","key":"421_CR6","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","volume":"62","author":"CW Yancy","year":"2013","unstructured":"Yancy CW, Jessup M, Bozkurt B, Butler J, Casey de Jr, Drazner MH, et al. 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2013;62(16):e147\u2013239. \n                      https:\/\/doi.org\/10.1016\/j.jacc.2013.05.019\n                      \n                    .","journal-title":"J Am Coll Cardiol"},{"issue":"27","key":"421_CR7","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the heart failure association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129\u2013200. \n                      https:\/\/doi.org\/10.1093\/eurheartj\/ehw128\n                      \n                    .","journal-title":"Eur Heart J"},{"key":"421_CR8","unstructured":"Acute Heart Failure Syndromes. Critical issues in the evaluation and management of adult patients presenting to the emergency department with acute heart failure syndromes. American College of Emergency Medicine, May, 2007. \n                      https:\/\/www.acep.org\/patient-care\/clinical-policies\/acute-heart-failure-syndromes\/#sm.00000ixjak0swgfqwwnufn8dak1b0\n                      \n                    ."},{"issue":"2","key":"421_CR9","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.ajem.2014.09.009","volume":"33","author":"P Alexander","year":"2015","unstructured":"Alexander P, Alkhawam L, Curry J, Levy P, Pang PS, Storrow AB, et al. Lack of evidence for intravenous vasodilators in ED patients with acute heart failure: a systematic review. Am J Emerg Med. 2015;33(2):133\u201341. \n                      https:\/\/doi.org\/10.1016\/j.ajem.2014.09.009\n                      \n                    .","journal-title":"Am J Emerg Med"},{"key":"421_CR10","volume-title":"Tintinalli\u2019s emergency medicine: a comprehensive study guide","author":"SP Collins","year":"2016","unstructured":"Collins SP, Storrow AB. Acute heart failure. In: Tintinalli JE, Stapczynski JS, Ma OJ, et al., editors. Tintinalli\u2019s emergency medicine: a comprehensive study guide. New York: McGraw-Hill Education; 2016."},{"issue":"Suppl 2","key":"421_CR11","first-page":"S7","volume":"2","author":"GC Fonarow","year":"2001","unstructured":"Fonarow GC. The treatment targets in acute decompensated heart failure. Rev Cardiovasc Med. 2001;2(Suppl 2):S7\u2013S12.","journal-title":"Rev Cardiovasc Med"},{"key":"421_CR12","doi-asserted-by":"publisher","first-page":"CD005151","DOI":"10.1002\/14651858.CD005151.pub2","volume":"8","author":"A Wakai","year":"2013","unstructured":"Wakai A, McCabe A, Kidney R, Brooks SC, Seupaul RA, Diercks DB, et al. Nitrates for acute heart failure syndromes. Cochrane Database Syst Rev. 2013;8:CD005151. \n                      https:\/\/doi.org\/10.1002\/14651858.CD005151.pub2\n                      \n                    .","journal-title":"Cochrane Database Syst Rev"},{"issue":"8327","key":"421_CR13","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/S0140-6736(83)92025-1","volume":"1","author":"GI Nelson","year":"1983","unstructured":"Nelson GI, Silke B, Ahuja RC, Hussain M, Taylor SH. Haemodynamic advantages of isosorbide dinitrate over frusemide in acute heart-failure following myocardial infarction. Lancet. 1983;1(8327):730\u20133.","journal-title":"Lancet"},{"issue":"1","key":"421_CR14","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1097\/00005344-198707000-00006","volume":"10","author":"SP Verma","year":"1987","unstructured":"Verma SP, Silke B, Hussain M, Nelson GIC, Reynolds GW, Richmond A, et al. First-line treatment of left ventricular failure complicating acute myocardial infarction: a randomised evaluation of immediate effects of diuretic, venodilator, arteriodilator, and positive inotropic drugs on left ventricular function. J Cardiovasc Pharmacol. 1987;10(1):38\u201346.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"4","key":"421_CR15","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S1071-9164(98)90232-9","volume":"4","author":"JF Beltrame","year":"1998","unstructured":"Beltrame JF, Zeitz CJ, Unger SA, Brennan RJ, Hunt A, Moran JL, et al. Nitrate therapy is an alternative to furosemide\/morphine therapy in the management of acute cardiogenic pulmonary edema. J Card Fail. 1998;4(4):271\u20139.","journal-title":"J Card Fail"},{"issue":"12","key":"421_CR16","first-page":"1531","volume":"287","author":"Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF)","year":"2002","unstructured":"Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF). Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA. 2002;287(12):1531\u201340 Erratum in: JAMA 2002 Aug 7;288(5):577.","journal-title":"JAMA"},{"issue":"9100","key":"421_CR17","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/S0140-6736(97)08417-1","volume":"351","author":"G Cotter","year":"1998","unstructured":"Cotter G, Metzkor E, Kaluski E, Faigenberg Z, Miller R, Simovitz A, et al. Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. Lancet. 1998;351(9100):389\u201393.","journal-title":"Lancet"},{"issue":"2","key":"421_CR18","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.annemergmed.2007.02.022","volume":"50","author":"P Levy","year":"2007","unstructured":"Levy P, Compton S, Welch R, Delgado G, Jennett A, Penugonda N, et al. Treatment of severe decompensated heart failure with high-dose intravenous nitroglycerin: a feasibility and outcome analysis. Ann Emerg Med. 2007;50(2):144\u201352.","journal-title":"Ann Emerg Med"},{"issue":"3","key":"421_CR19","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.jacc.2008.02.083","volume":"52","author":"W Mullens","year":"2008","unstructured":"Mullens W, Abrahams Z, Francis GS, Skouri HN, Starling RC, Young JB, et al. Sodium nitroprusside for advanced low-output heart failure. J Am Coll Cardiol. 2008;52(3):200\u20137. \n                      https:\/\/doi.org\/10.1016\/j.jacc.2008.02.083\n                      \n                    .","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"421_CR20","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.annemergmed.2006.10.024","volume":"49","author":"SM Silvers","year":"2007","unstructured":"Silvers SM, Howell JM, Kosowsky JM, Rokos IC, Jagoda AS, American College of Emergency Physicians. Clinical policy: critical issues in the evaluation and management of adult patients presenting to the emergency department with acute heart failure syndromes. Ann Emerg Med. 2007;49(5):627\u201369.","journal-title":"Ann Emerg Med"},{"key":"421_CR21","doi-asserted-by":"publisher","unstructured":"Long B, Koyfman A, Gottlieb M. Management of heart failure in the emergency department setting: an evidence-based review of the literature. J Emerg Med. 2018. \n                      https:\/\/doi.org\/10.1016\/j.jemermed.2018.08.002\n                      \n                    .","DOI":"10.1016\/j.jemermed.2018.08.002"},{"issue":"23","key":"421_CR22","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","volume":"316","author":"CONSENSUS Trial Study Group","year":"1987","unstructured":"CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316(23):1429\u201335.","journal-title":"N Engl J Med"},{"issue":"5","key":"421_CR23","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1056\/NEJM199108013250501","volume":"325","author":"S Yusuf","year":"1991","unstructured":"SOLVD Investigators, Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325(5):293\u2013302.","journal-title":"N Engl J Med"},{"issue":"6","key":"421_CR24","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1161\/01.CIR.94.6.1316","volume":"94","author":"D Annane","year":"1996","unstructured":"Annane D, Bellissant E, Pussard E, Asmar R, Lacombe F, Lanata E, et al. Placebo-controlled, randomized, double-blind study of intravenous enalaprilat efficacy and safety in acute cardiogenic pulmonary edema. Circulation. 1996;94(6):1316\u201324.","journal-title":"Circulation"},{"issue":"1","key":"421_CR25","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1056\/NEJMoa1100171","volume":"365","author":"CM O'Connor","year":"2011","unstructured":"O'Connor CM, Starling RC, Hernandez AF, Armstrong PW, Dickstein K, Hasselblad V, et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med. 2011;365(1):32\u201343. \n                      https:\/\/doi.org\/10.1056\/NEJMoa1100171\n                      \n                    .","journal-title":"N Engl J Med"},{"issue":"15","key":"421_CR26","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1001\/jama.293.15.1900","volume":"293","author":"JD Sackner-Bernstein","year":"2005","unstructured":"Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA. 2005;293(15):1900\u20135.","journal-title":"JAMA"},{"issue":"4","key":"421_CR27","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.ahj.2013.12.023","volume":"167","author":"WF Peacock","year":"2014","unstructured":"Peacock WF, Chandra A, Char D, Collins S, der Sahakian G, Ding L, et al. Clevidipine in acute heart failure: results of the a study of blood pressure control in acute heart failure-a pilot study (PRONTO). Am Heart J. 2014;167(4):529\u201336. \n                      https:\/\/doi.org\/10.1016\/j.ahj.2013.12.023\n                      \n                    .","journal-title":"Am Heart J"},{"issue":"30","key":"421_CR28","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1093\/eurheartj\/ehx196","volume":"38","author":"PS Pang","year":"2017","unstructured":"\u2022 Pang PS, Butler J, Collins SP, et al. Biased ligand of the angiotensin II type 1 receptor in patients with acute heart failure: a randomized, double-blind, placebo-controlled, phase IIB, dose ranging trial (BLAST-AHF). Eur Heart J. 2017;38(30):2364\u201373. \n                      https:\/\/doi.org\/10.1093\/eurheartj\/ehx196\n                      \n                    . This randomized controlled trial investigated the safety and efficacy of an angiotensin II type I receptor ligand, for use in the treatment of acute heart failure.","journal-title":"Eur Heart J"},{"issue":"3","key":"421_CR29","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.jchf.2014.09.008","volume":"3","author":"GM Felker","year":"2015","unstructured":"Felker GM, Butler J, Collins SP, Cotter G, Davison BA, Ezekowitz JA, et al. Heart failure therapeutics on the basis of a biased ligand of the angiotensin-2 type 1 receptor. Rationale and design of the BLAST-AHF study (biased ligand of the angiotensin receptor study in acute heart failure). JACC Heart Fail. 2015;3(3):193\u2013201. \n                      https:\/\/doi.org\/10.1016\/j.jchf.2014.09.008\n                      \n                    .","journal-title":"JACC Heart Fail"},{"issue":"20","key":"421_CR30","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1056\/NEJMoa1601895","volume":"376","author":"M Packer","year":"2017","unstructured":"\u2022 Packer M, O'Connor C, McMurray JJV, et al. TRUE-AHF Investigators. Effect of ularitide on cardiovascular mortality in acute heart failure. N Engl J Med. 2017;376(20):1956\u201364. \n                      https:\/\/doi.org\/10.1056\/NEJMoa1601895\n                      \n                    . This randomized controlled trial investigated ularitide, an analogue of the natural vasodilator urodilantin, in the treatment of acute heart failure.","journal-title":"N Engl J Med"},{"key":"421_CR31","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/j.ahj.2005.01.022","volume":"150","author":"V Mitrovic","year":"2005","unstructured":"Mitrovic V, L\u00fcss H, Nitsche K, et al. Effects of the renal natriuretic peptide uro- dilatin (ularitide) in patients with decom- pensated chronic heart failure: a double- blind, placebo-controlled, ascending-dose trial. Am Heart J. 2005;150:1239.","journal-title":"Am Heart J"},{"key":"421_CR32","doi-asserted-by":"crossref","unstructured":"Mitrovic V, Seferovic PM, Simeunovic D, Ristic AD, Miric M, Moiseyev VS, et al. Haemodynamic and clinical effects of ularitide in decompensated heart failure. Eur Heart J. 2006;27:2823\u201332.","DOI":"10.1093\/eurheartj\/ehl337"},{"issue":"9860","key":"421_CR33","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(12)61855-8","volume":"381","author":"JR Teerlink","year":"2013","unstructured":"\u2022 Teerlink JR, Cotter G, Davison BA, et al. RELAXin in Acute Heart Failure (RELAX-AHF) Investigators. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet. 2013;381(9860):29\u201339. \n                      https:\/\/doi.org\/10.1016\/S0140-6736(12)61855-8\n                      \n                    . This randomized controlled trial investigated the effects of serelaxin, a recombinant of human relaxin-2, responsible for hemodynamic changes in pregnancy, in the treatment of acute heart failure.","journal-title":"Lancet"},{"issue":"2","key":"421_CR34","doi-asserted-by":"publisher","first-page":"R267","DOI":"10.1152\/ajpregu.00156.2011","volume":"301","author":"KP Conrad","year":"2011","unstructured":"Conrad KP. Maternal vasodilation in pregnancy: the emerging role of relaxin. Am J Physiol Regul Integr Comp Physiol. 2011;301(2):R267\u201375. \n                      https:\/\/doi.org\/10.1152\/ajpregu.00156.2011\n                      \n                    .","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"2","key":"421_CR35","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s11897-010-0010-z","volume":"7","author":"SL Teichman","year":"2010","unstructured":"Teichman SL, Unemori E, Teerlink JR, Cotter G, Metra M. Relaxin: review of biology and potential role in treating heart failure. Curr Heart Fail Rep. 2010;7(2):75\u201382. \n                      https:\/\/doi.org\/10.1007\/s11897-010-0010-z\n                      \n                    .","journal-title":"Curr Heart Fail Rep"},{"issue":"2","key":"421_CR36","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.ahj.2011.10.009","volume":"163","author":"P Ponikowski","year":"2012","unstructured":"Ponikowski P, Metra M, Teerlink JR, et al. Design of the RELAXin in acute heart failure study. Am Heart J. 2012;163(2):149\u201355.e1. \n                      https:\/\/doi.org\/10.1016\/j.ahj.2011.10.009\n                      \n                    .","journal-title":"Am Heart J"},{"key":"421_CR37","unstructured":"RELAXin in acute heart failure-2 - RELAX-AHF-2. American College of Cardiology, May 8, 2017. \n                      https:\/\/www.acc.org\/latest-in-cardiology\/clinical-trials\/2017\/05\/07\/16\/09\/relax-ahf-2\n                      \n                    ."},{"issue":"11","key":"421_CR38","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1093\/eurjhf\/hfq133","volume":"12","author":"SP Collins","year":"2010","unstructured":"Collins SP, Pang PS, Lindsell CJ, Kyriacou DN, Storrow AB, Hollander JE, et al. International variations in the clinical, diagnostic, and treatment characteristics of emergency department patients with acute heart failure syndromes. Eur J Heart Fail. 2010;12(11):1253\u201360. \n                      https:\/\/doi.org\/10.1093\/eurjhf\/hfq133\n                      \n                    .","journal-title":"Eur J Heart Fail"},{"key":"421_CR39","unstructured":"Novartis heart drug portfolio hit by failed serelaxin study. Reuters, March 22, 2017 \n                      http:\/\/www.reuters.com\/article\/ us-novartis-heart-idUSKBN16T0QG\n                      \n                    ."}],"container-title":["Current Heart Failure Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-019-0421-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11897-019-0421-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-019-0421-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T18:56:39Z","timestamp":1581965799000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11897-019-0421-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["421"],"URL":"https:\/\/doi.org\/10.1007\/s11897-019-0421-4","relation":{},"ISSN":["1546-9530","1546-9549"],"issn-type":[{"value":"1546-9530","type":"print"},{"value":"1546-9549","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"14 February 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Daniel B. Holt Jr. declares no conflicts of interest.Peter S. Pang reports grants from AHA, NHLBI, and AHRQ during the conduct of the study; grants from Roche; personal fees, non-financial support, and other from Novartis, BMS, and Trevena; personal fees and non-financial support from Baxter; and other from Orthodiagnostics and Edwards outside the submitted work, and associate editor for JACC Heart failure, and Editorial board for the Journal of Cardiac Failure.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}